论文部分内容阅读
目的探讨米非司酮单独应用及与宫瘤消胶囊联合应用治疗子宫肿瘤的临床疗效。方法选取2013年5月至2015年5月间海南省海口市琼山妇产科医院收治的200例子宫肌瘤患者,采用随机数字表法分为观察组和对照组,每组100例。观察组患者采用宫瘤消胶囊联合米非司酮治疗,对照组患者采用米非司酮单独治疗。比较两组患者的治疗效果。结果观察组患者的总有效率为97.0%,明显优于对照组的67.0%,组间差异有统计学意义(P<0.05)。观察组患者治疗后子宫体积为(30.3±4.2)cm~3,肿瘤体积为(102.6±11.1)cm~3,对照组分别为(51.1±5.4)cm~3和(123.7±9.7)cm~3,两组比较,差异有统计学意义(P<0.05)。结论子宫肌瘤患者应用米非司酮联合宫瘤消胶囊治疗效果显著,可改善患者症状,缩小肿瘤体积,安全可靠,值得临床推广应用。
Objective To investigate the clinical efficacy of mifepristone alone and in combination with Gongyu Xiao capsule in the treatment of uterine tumors. Methods From May 2013 to May 2015, 200 cases of uterine leiomyoma admitted to Qiongshan Obstetrics and Gynecology Hospital of Haikou City, Hainan Province were divided into observation group and control group using random number table method, with 100 cases in each group. Patients in the observation group were treated with Miyao capsule and mifepristone, while patients in the control group were treated with mifepristone alone. The treatment effect of two groups of patients was compared. Results The total effective rate in observation group was 97.0%, which was significantly better than that in control group (67.0%). The difference between the two groups was statistically significant (P <0.05). The volume of the uterus in the observation group was (30.3 ± 4.2) cm ~ 3 and the volume of the tumor was (102.6 ± 11.1) cm ~ 3 in the observation group and 51.1 ± 5.4 cm ~ (123.7 ± 9.7) cm ~ , The difference between the two groups was statistically significant (P <0.05). Conclusion The treatment of uterine fibroids with mifepristone combined with Miyaoma capsule is significant, can improve the symptoms of patients, reduce tumor size, safe and reliable, worthy of clinical promotion and application.